Insider Buying: Sernova Corp. (TSE:SVA) Director Buys C$12,400.00 in Stock

Sernova Corp. (TSE:SVA) Director Steven Sangha acquired 40,000 shares of the business’s stock in a transaction dated Monday, July 15th. The stock was acquired at an average cost of C$0.31 per share, with a total value of C$12,400.00.

Sernova Trading Down 1.7 %

TSE:SVA opened at C$0.30 on Thursday. The company has a fifty day moving average of C$0.33 and a 200 day moving average of C$0.48. Sernova Corp. has a 52 week low of C$0.27 and a 52 week high of C$0.98. The company has a quick ratio of 18.11, a current ratio of 1.20 and a debt-to-equity ratio of 16.55. The firm has a market capitalization of C$89.51 million, a P/E ratio of -2.27 and a beta of 1.53.

Sernova (TSE:SVA) last posted its quarterly earnings results on Friday, June 14th. The company reported C($0.03) EPS for the quarter, meeting analysts’ consensus estimates of C($0.03). On average, research analysts predict that Sernova Corp. will post -0.08 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Raymond James set a C$1.50 price target on shares of Sernova and gave the company a “market perform” rating in a report on Thursday, April 4th.

Sernova Company Profile

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection.